Neoadjuvant Chemotherapy Takes the Lead in Prolonging Survival for Esophageal Squamous Cell Carcinoma

In the realm of esophageal squamous cell carcinoma (ESCC), the battle between neoadjuvant chemotherapy (NAC) and adjuvant chemotherapy (AC) takes center stage. A squad of 684 ESCC patients engaged in this retrospective face-off at Henan Cancer Hospital. Post Propensity Score Matching (PSM), the NAC squad flexed its muscles, showcasing prolonged overall survival (OS) and disease-free survival (DFS), while reducing total and local recurrence rates. The study concludes: NAC plus surgery emerges as the victorious combo for clinical stage II and III ESCC patients.